Big Pharma e uno SPAC da 3,5 mld USD portano la deeptech svizzera sullo scacchiere globale
ValIndex counted 121 M&A-relevant filings in the Swiss commercial register in the week of May 25–29, 2026 — a four-day, Whit-Monday-shortened week — alongside ten press-reported cross-border transactions.
Eli Lilly agreed on May 26, 2026 to acquire Swiss clinical-stage biotech LimmaTech Biologics for up to USD 780 million, part of a vaccine sweep worth up to roughly USD 4 billion across three developers.
Terra Quantum, the St. Gallen quantum-technology company, agreed a Nasdaq listing via SPAC at a USD 3.5 billion equity valuation.
On May 26, Eli Lilly said it would buy three vaccine developers for up to roughly $4 billion, building an infectious-disease franchise in a single move. The Swiss anchor was LimmaTech Biologics — St. Gallen-founded, Schlieren-based, spun from GlycoVaxyn's glyco-conjugation science — for up to $780 million in milestones. LimmaTech's programs target antibiotic-resistant bacteria, including a potential first-in-class gonorrhea vaccine. The company has no revenue; what Lilly bought is the pipeline and the thesis that antibiotic resistance is now a buy-side priority. It is the clearest signal yet that a Swiss clinical-stage biotech's most likely exit is a nine-figure trade sale to a US major.
The same week offered the other escape route. Terra Quantum, the St. Gallen quantum-computing and quantum-security firm, agreed to list on Nasdaq via an Axiom SPAC at a $3.5 billion equity valuation — raised from a $3.25 billion letter of intent with a different SPAC just a month earlier. Where the prior weeks' deeptech stories were quiet trade sales of capital-starved startups, this is the opposite: Swiss deeptech reaching public markets at multi-billion scale, with up to ~$190 million of fresh capital to spend on R&D and its own acquisitions.
In wealth management, the roll-up kept exporting itself. Zug-based Cinerius Financial Partners took a majority of Hamburg's HONESTAS Group, crossing €18 billion in assets and entering northern Germany, with the founders rolling equity into the platform. Around it, the tuck-ins: Swiss Life on the TELIS advisory group, Convotis on e-government software house Glaux, France's Elis on Swiss laundry firm Wäsche Perle.
The registry beneath it all: 121 M&A-relevant filings in a four-day Whit-Monday week (120 the week before), 268 bankruptcies, 196 liquidations. The cycle took its own — Zug crypto-fund Creed & Bear and ETH water-tech spinoff onCyt Microbiology both entered liquidation. All figures from the Swiss commercial register.
One Story Deeper
onCyt Microbiology is the kind of estate worth watching. An Eawag/ETH Zürich spinoff, it built the first fully automated online flow cytometer for round-the-clock microbe monitoring in drinking water — a genuine instrumentation breakthrough. The Zurich district court granted a definitive moratorium on February 27, 2026.
What sits in the estate is real: the online-cytometry instrument IP, its patents, and utility-sector client relationships in a regulated, recurring-revenue niche. This is exactly the asset a water-technology or lab-instrumentation acquirer buys out of a moratorium for a fraction of the venture capital that built it — the same distressed-deeptech pattern running through every edition this month, here in water rather than composites or quantum.
The Tape — 6 transactions
May 26 PRESS | Eli Lilly and Company ← LimmaTech Biologics AGZH Part of Lilly's ~$4bn three-target infectious-disease sweep announced May 26. LimmaTech (St. Gallen-founded, Schlieren-based, GlycoVaxyn lineage) brings Phase-stage vaccines against S. aureus, gonorrhea and chlamydia. Up to $780m including milestones — the Swiss anchor of the deal. Up to USD 780M (deal value) |
May 26 PRESS | Axiom Intelligence Acquisition Corp 1 ← Terra Quantum AGSG The St. Gallen quantum-computing and quantum-security firm agreed a Nasdaq SPAC listing at a ~$3.5bn equity valuation (ticker TQ, H2 2026), up from a $3.25bn LOI with a different SPAC a month earlier. Up to ~$190m gross proceeds fund R&D, enterprise sales and M&A. USD 3.5B equity value |
May 28 PRESS | Cinerius Financial Partners ← HONESTAS GroupZG Zug-based wealth platform Cinerius took a majority of Hamburg's HONESTAS Group (Finanzmanagement + Family Office), crossing EUR 18bn AUM and entering northern Germany. Founders Carolin Tsalkas and Stefan Kirchner roll equity into Cinerius. Undisclosed |
May 28 PRESS | Swiss Life Deutschland ← TELIS Gruppe Swiss Life's German arm moved on the TELIS financial-advisory group, extending its tied-agent distribution reach in Germany — the insurer buying distribution rather than building it. Undisclosed |
May 27 PRESS | Convotis Schweiz ← Glaux GroupBE Convotis Schweiz acquired e-government software house Glaux Group, consolidating Swiss public-sector digitalization vendors — a sticky, reference-driven niche where incumbents rarely change hands. Undisclosed |
May 27 PRESS | Elis ← Wäsche Perle French textile-services major Elis bought Swiss laundry firm Wäsche Perle, a classic route-density roll-up: foreign strategics keep consolidating Swiss industrial-laundry capacity region by region. Undisclosed |
Unlock the signals — free
Pre-deal signals scored before the press, federal procurement prints, the forward court calendar and buyable estates. Free, every Friday.
Free weekly newsletter. Unsubscribe anytime.
Based on 4,891 SOGC/SHAB publications processed this week. M&A data sourced from Swiss commercial registry filings (121 SOGC), press-reported transactions via web intelligence (10 EXA), and startup funding from Startupticker, Tech.eu, and company disclosures (0 rounds). Company distress scoring based on proprietary multi-signal model across 113,000 Swiss companies. Valuation benchmarks supplemented from Deloitte Swiss M&A reports and Dealsuite DACH data.
ValIndex scores every Swiss merger, board change and distress signal across 113,000 companies, daily. Request platform access to see which names surface next. Request access →